GTx, Inc. is a company of pioneering and driven individuals who are delivering better medicines with new science through established pathways. Our recognized scientific expertise is in the discovery and development of novel, selective small molecules that target established hormone pathways to prevent and treat cancer, fractures and bone loss, muscle loss and other serious medical conditions.
Our most advanced drug discovery and development programs are focused on small molecules that selectively modulate the effects of estrogens and androgens.
GTx's newest product candidate is Capesaris™ (GTx-758), which is a selective ER alpha agonist being developed for first line treatment of advanced prostate cancer. GTx-758 has the potential to achieve medical castration without causing bone loss or hot flashes.
GTx is developing Ostarine™ (GTx-024) and other selective androgen receptor modulators, or SARMs, for the prevention and treatment of muscle loss in patients with cancer and for other muscle wasting diseases.